BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
Company Research
Source: PR Newswire
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax (Ascentage Pharma), Sonrotoclax (BeOne Medicines), LP-118 and LP-108 (Newave Pharmaceutical), and others, reports DelveInsight.LAS VEGAS, Feb. 12, 2026 /PRNewswire/ -- DelveInsight's BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Myelodysplastic Syndrome, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Non-Hodgkin Lymphoma, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging BCL-2 inhibitors, market share of individual therapies, and current and forec
Show less
Read more
Impact Snapshot
Event Time:
ADAG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAG alerts
High impacting Adagene Inc. - ADS, each representing 1.25 ordinary shares news events
Weekly update
A roundup of the hottest topics
ADAG
News
- BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsightPR Newswire
- ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership ForgingPR Newswire
- ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership ForgingPR Newswire
- Adagene Provides Business Update and 2026 ObjectivesGlobeNewswire
- Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)GlobeNewswire
ADAG
Sec Filings
- 1/29/26 - Form SCHEDULE
- 1/23/26 - Form 6-K
- 1/12/26 - Form EFFECT
- ADAG's page on the SEC website